FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics, particularly an aqueous composition containing water and protein of molecular weight more than approximately 47 kDa, and to methods for preparing said composition. The aqueous composition under the present invention is rich in proteins and has the low conduction levels ensured by the low content of ionic excipients. The amount of the invention also involves such compositions containing water and proteins which have a low osmolarity or hydrodynamic diameter which is less approximately by 50% thereof in a buffer solution in the given concentration with protein in the composition having a molecular weight more than approximately 47 kDa.
EFFECT: invention provides protein stability in the solution.
42 cl, 31 ex, 77 tbl
Title | Year | Author | Number |
---|---|---|---|
PROTEIN COMPOSITIONS AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2659431C2 |
STABLE COMPOSITIONS WITH HIGH CONCENTRATIONS OF PROTEINS OF HUMAN ANTIBODIES AGAINST TNF-ALPHA | 2010 |
|
RU2560701C2 |
STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ADALIMUMAB | 2014 |
|
RU2664736C2 |
RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
LIQUID COMPOSITION OF AN ANTIBODY AGAINST TNF ALPHA | 2018 |
|
RU2756619C2 |
LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
PHARMACEUTICAL FORMULATION CONTAINING BEVACIZUMAB | 2021 |
|
RU2819797C1 |
Authors
Dates
2013-01-27—Published
2008-11-28—Filed